The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro
出版年份 2017 全文链接
标题
The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro
作者
关键词
-
出版物
PHARMACOGENOMICS JOURNAL
Volume 18, Issue 3, Pages 487-493
出版商
Springer Nature
发表日期
2017-11-21
DOI
10.1038/tpj.2017.45
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
- (2016) Henry Ginsberg et al. DIABETES OBESITY & METABOLISM
- Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
- (2016) K. Cusi et al. DIABETES OBESITY & METABOLISM
- Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes
- (2016) S. Mudaliar et al. DIABETES OBESITY & METABOLISM
- Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
- (2016) T. Blevins et al. DIABETES OBESITY & METABOLISM
- Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
- (2016) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial
- (2016) G. Grunberger et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
- (2016) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
- (2016) S. Garg et al. DIABETES OBESITY & METABOLISM
- Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study
- (2016) S. Garg et al. DIABETES OBESITY & METABOLISM
- Hepato-preferential insulins: Is this the end, or the end of the beginning?
- (2016) D. L. Russell-Jones DIABETES OBESITY & METABOLISM
- The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
- (2016) Rosellina Margherita Mancina et al. GASTROENTEROLOGY
- The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans
- (2016) Panu K. Luukkonen et al. JOURNAL OF HEPATOLOGY
- Combined effects of thePNPLA3rs738409,TM6SF2rs58542926, andMBOAT7rs641738 variants on NAFLD severity: a multicenter biopsy-based study
- (2016) Marcin Krawczyk et al. JOURNAL OF LIPID RESEARCH
- PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery
- (2016) Marcin Krawczyk et al. Surgery for Obesity and Related Diseases
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- The dual and opposite role of theTM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis
- (2015) Carlos J. Pirola et al. HEPATOLOGY
- The Genetic Variant I148M inPNPLA3Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans
- (2015) Marketa Kovarova et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial
- (2015) Eleonora Scorletti et al. JOURNAL OF HEPATOLOGY
- PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity
- (2015) Alison Mondul et al. JOURNAL OF NUTRITION
- Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
- (2015) Paola Dongiovanni et al. Biomed Research International
- PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
- (2014) Carlo Pirazzi et al. HUMAN MOLECULAR GENETICS
- PNPLA3gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
- (2014) Jiayun Shen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Reply to “Hepatocellular carcinoma and the Newcastle-upon-Tyne area”
- (2014) Quentin M. Anstee et al. JOURNAL OF HEPATOLOGY
- Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk
- (2014) Oddgeir L Holmen et al. NATURE GENETICS
- Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
- (2014) Julia Kozlitina et al. NATURE GENETICS
- Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function
- (2013) Piero Pingitore et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
- (2013) M. C. Moore et al. DIABETES
- Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
- (2013) V. P. Sinha et al. DIABETES OBESITY & METABOLISM
- PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease
- (2013) Luca Valenti et al. DIGESTIVE AND LIVER DISEASE
- Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)
- (2013) Ajay Duseja et al. Hepatology International
- PNPLA3 I148M polymorphism and progressive liver disease
- (2013) Paola Dongiovanni WORLD JOURNAL OF GASTROENTEROLOGY
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
- (2012) Naga Chalasani et al. GASTROENTEROLOGY
- Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
- (2012) Arian Mashhood et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study
- (2011) Neeraj Bhala et al. HEPATOLOGY
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
- (2010) Mustafa S. Ascha et al. HEPATOLOGY
- Heritability of Nonalcoholic Fatty Liver Disease
- (2009) Jeffrey B. Schwimmer et al. GASTROENTEROLOGY
- A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis
- (2009) Shaoqing He et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ethnic differences in hepatic steatosis: An insulin resistance paradox?
- (2008) Richard Guerrero et al. HEPATOLOGY
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
- (2008) Stefano Romeo et al. NATURE GENETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started